Overall, 83 (69.7%) of 119 tumour categories showed a detectable ACE2 expression, with 53 (44.5%) tumour categories showing at least in one case a moderate positivity and 37 (31.1%) tumour categories with at least one strongly positive case (Supplementary Table S1). This evidence concerns the gene ACE2 and neoplasm.